Vergote I - Search Results

1

Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.

Vergote I, Gonzalez-Martin A, Lorusso D, Gourley C, Mirza MR, Kurtz JE, Okamoto A, Moore K, Kridelka F, McNeish I, Reuss A, Votan B, du Bois A, Mahner S, Ray-Coquard I, Kohn EC, Berek JS, Tan DSP, Colombo N, Zang R, Concin N, O'Donnell D, Rauh-Hain A, Herrington CS, Marth C, Poveda A, Fujiwara K, Stuart GCE, Oza AM, Bookman MA; participants of the 6th Gynecologic Cancer InterGroup (GCIG) Ovarian Cancer Consensus Conference on Clinical Research. Vergote I, et al. Lancet Oncol. 2022 Aug;23(8):e374-e384. doi: 10.1016/S1470-2045(22)00139-5. Lancet Oncol. 2022. PMID: 35901833 Free PMC article. Review.

2

Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer.

D'Agostino G, Amant F, Berteloot P, Scambia G, Vergote I. D'Agostino G, et al. Among authors: vergote i. Gynecol Oncol. 2003 Mar;88(3):266-9. doi: 10.1016/s0090-8258(03)00011-8. Gynecol Oncol. 2003. PMID: 12648573 Clinical Trial.

3

Treatment of patients with early epithelial ovarian cancer.

Vergote I, Trimbos BJ. Vergote I, et al. Curr Opin Oncol. 2003 Nov;15(6):452-5. doi: 10.1097/00001622-200311000-00008. Curr Opin Oncol. 2003. PMID: 14624228 Review.

4

Intraperitoneal chemotherapy in ovarian cancer remains experimental.

Gore M, du Bois A, Vergote I. Gore M, et al. Among authors: vergote i. J Clin Oncol. 2006 Oct 1;24(28):4528-30. doi: 10.1200/JCO.2006.06.0376. J Clin Oncol. 2006. PMID: 17008689 No abstract available.

5

Ovarian cancer.

Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, Vergote I. Colombo N, et al. Among authors: vergote i. Crit Rev Oncol Hematol. 2006 Nov;60(2):159-79. doi: 10.1016/j.critrevonc.2006.03.004. Epub 2006 Oct 2. Crit Rev Oncol Hematol. 2006. PMID: 17018256 Review.

6

Modulation of CA-125 tumor marker shedding in ovarian cancer cells by erlotinib or cetuximab.

Marth C, Egle D, Auer D, Rössler J, Zeimet AG, Vergote I, Daxenbichler G. Marth C, et al. Among authors: vergote i. Gynecol Oncol. 2007 Jun;105(3):716-21. doi: 10.1016/j.ygyno.2007.02.010. Epub 2007 Mar 21. Gynecol Oncol. 2007. PMID: 17376521

7

Gynecologic oncology in pregnancy.

Amant F, Van Calsteren K, Vergote I, Ottevanger N. Amant F, et al. Among authors: vergote i. Crit Rev Oncol Hematol. 2008 Sep;67(3):187-95. doi: 10.1016/j.critrevonc.2008.01.006. Epub 2008 Mar 4. Crit Rev Oncol Hematol. 2008. PMID: 18296060 Review.

8

A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer.

Vergote I, Calvert H, Kania M, Kaiser C, Zimmermann AH, Sehouli J. Vergote I, et al. Eur J Cancer. 2009 May;45(8):1415-23. doi: 10.1016/j.ejca.2008.12.013. Epub 2009 Jan 23. Eur J Cancer. 2009. PMID: 19168349 Clinical Trial.

9

Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO staging system.

Petru E, Lück HJ, Stuart G, Gaffney D, Millan D, Vergote I; Gynecologic Cancer Intergroup (GCIG). Petru E, et al. Among authors: vergote i. Eur J Obstet Gynecol Reprod Biol. 2009 Apr;143(2):69-74. doi: 10.1016/j.ejogrb.2008.12.015. Epub 2009 Feb 4. Eur J Obstet Gynecol Reprod Biol. 2009. PMID: 19195765

10

Gynecologic cancers in pregnancy: guidelines of an international consensus meeting.

Amant F, Van Calsteren K, Halaska MJ, Beijnen J, Lagae L, Hanssens M, Heyns L, Lannoo L, Ottevanger NP, Vanden Bogaert W, Ungar L, Vergote I, du Bois A. Amant F, et al. Among authors: vergote i. Int J Gynecol Cancer. 2009 May;19 Suppl 1:S1-12. doi: 10.1111/IGC.0b013e3181a1d0ec. Int J Gynecol Cancer. 2009. PMID: 19509538

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

874 results

Search Page